Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00151333 | Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD) | PHASE2 | COMPLETED | 16 | — | — | Feb 1, 2005 | Apr 1, 2005 | Sep 4, 2009 | 3 | United States |
| Name | Type | Description |
|---|---|---|
| SRA-333 | DRUG | - |
Inclusion Criteria: * Diagnosis of probable AD according to the NINCDS-ADRDA criteria. * Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive. * Able to give informed consent. Patient's caregiver must consent to participate in the study. Exclusion Criteria: * Significan...